Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

George J Hutton

Showing results (21-30 of 48) with videos related to

Pageof 5
Sort By:
Multiple Sclerosis and Related Disorders|January 10, 2022
Elsberg syndrome following acute immunosuppressive treatment for multiple sclerosis relapseNatasha A Choudhury, Rhaisa M Castrodad-Molina, George J Hutton, et al.
Research in Social & Administrative Pharmacy : RSAP|March 16, 2020
Use of disease modifying agents in patients with multiple sclerosis: Analysis of ten years of national dataJagadeswara R Earla, Rutugandha Paranjpe, Nandita Kachru, et al.
Multiple Sclerosis and Related Disorders|March 12, 2022
FACTORS ASSOCIATED WITH SWITCHING FROM INJECTABLE TO ORAL DISEASE MODIFYING AGENTS AMONG PATIENTS WITH MULTIPLE SCLEROSISJieni Li, Soumya G Chikermane, Jagadeswara R Earla, et al.
Journal of the Neurological Sciences|September 23, 2016
Newly diagnosed ganglioglioma in an adult patient with multiple sclerosisJacob J Mandel, Eric A Goethe, Akash J Patel, et al.
Biomedicines|May 16, 2023
Health Disparities in Multiple Sclerosis among Hispanic and Black Populations in the United StatesMichael Z Moore, Carlos A Pérez, George J Hutton, et al.
Pharmacotherapy|May 9, 2023
Comparative adherence trajectories of oral disease-modifying agents in multiple sclerosisJagadeswara Rao Earla, Jieni Li, George J Hutton, et al.
Multiple Sclerosis and Related Disorders|April 4, 2024
Association of oral disease-modifying agents and their adherence trajectories with annual relapses in multiple sclerosisJagadeswara Rao Earla, Jieni Li, George J Hutton, et al.
Biomedicines|December 1, 2020
Multiple Sclerosis in a Multi-Ethnic Population in Houston, Texas: A Retrospective AnalysisVicki Mercado, Deepa Dongarwar, Kristen Fisher, et al.
Clinical Pharmacology and Therapeutics|November 15, 2024
Infection Risk Associated with High-Efficacy Disease-Modifying Agents in Multiple Sclerosis: A Retrospective Cohort StudyJieni Li, George J Hutton, Tyler J Varisco, et al.
Multiple Sclerosis and Related Disorders|September 29, 2024
Factors associated with the initiation of high-efficacy disease-modifying agents over moderate-efficacy disease-modifying agents in multiple sclerosisJieni Li, George J Hutton, Tyler J Varisco, et al.
Pageof 5

Showing results (21-30 of 48) with videos related to

Sort By:
Pageof 5
Multiple Sclerosis and Related Disorders|January 10, 2022
Elsberg syndrome following acute immunosuppressive treatment for multiple sclerosis relapseNatasha A Choudhury, Rhaisa M Castrodad-Molina, George J Hutton, et al.
Research in Social & Administrative Pharmacy : RSAP|March 16, 2020
Use of disease modifying agents in patients with multiple sclerosis: Analysis of ten years of national dataJagadeswara R Earla, Rutugandha Paranjpe, Nandita Kachru, et al.
Multiple Sclerosis and Related Disorders|March 12, 2022
FACTORS ASSOCIATED WITH SWITCHING FROM INJECTABLE TO ORAL DISEASE MODIFYING AGENTS AMONG PATIENTS WITH MULTIPLE SCLEROSISJieni Li, Soumya G Chikermane, Jagadeswara R Earla, et al.
Journal of the Neurological Sciences|September 23, 2016
Newly diagnosed ganglioglioma in an adult patient with multiple sclerosisJacob J Mandel, Eric A Goethe, Akash J Patel, et al.
Biomedicines|May 16, 2023
Health Disparities in Multiple Sclerosis among Hispanic and Black Populations in the United StatesMichael Z Moore, Carlos A Pérez, George J Hutton, et al.
Pharmacotherapy|May 9, 2023
Comparative adherence trajectories of oral disease-modifying agents in multiple sclerosisJagadeswara Rao Earla, Jieni Li, George J Hutton, et al.
Multiple Sclerosis and Related Disorders|April 4, 2024
Association of oral disease-modifying agents and their adherence trajectories with annual relapses in multiple sclerosisJagadeswara Rao Earla, Jieni Li, George J Hutton, et al.
Biomedicines|December 1, 2020
Multiple Sclerosis in a Multi-Ethnic Population in Houston, Texas: A Retrospective AnalysisVicki Mercado, Deepa Dongarwar, Kristen Fisher, et al.
Clinical Pharmacology and Therapeutics|November 15, 2024
Infection Risk Associated with High-Efficacy Disease-Modifying Agents in Multiple Sclerosis: A Retrospective Cohort StudyJieni Li, George J Hutton, Tyler J Varisco, et al.
Multiple Sclerosis and Related Disorders|September 29, 2024
Factors associated with the initiation of high-efficacy disease-modifying agents over moderate-efficacy disease-modifying agents in multiple sclerosisJieni Li, George J Hutton, Tyler J Varisco, et al.
Pageof 5